Traws Pharma: TXM shows positive H5N1 data in non-human primates; FDA meeting planned H1 2025

Traws Pharma, Inc.

Single-dose TXM (480 mg) reduced lung viremia below quantitation vs up to 1x10^7 in controls after H5N1 challenge.
TXM-treated NHPs maintained stable weight vs 4.2% loss in controls (p<0.004).
Consistent efficacy across NHPs, ferrets (increased survival), and mice (complete survival, undetectable viremia).
Company plans FDA meeting in H1 2025 to discuss accelerated approval under the Animal Rule.
Investor event on March 31, 2025 at 10:00 AM ET to present TXM overview and next steps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.